Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease

被引：12

作者：

Lindberg, JS ^{[1
]}

机构：

[1] New Orleans Nephrol Associates, New Orleans, LA USA

来源：

KIDNEY INTERNATIONAL | 2005年 / 67卷

关键词：

cinacalcet HCl; calcimimetics; secondary hyperparathyroidism; PTH; serum calcium; serum phosphorus; Ca x P product;

D O I：

10.1111/j.1523-1755.2005.09505.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Epidemiologic, clinical, and basic scientific studies led to an explosion in our understanding of disorders of mineral metabolism in the chronic kidney disease (CKD) patient. These advances are not always translated into improved care of renal osteodystrophy in CKD-5 patients. The introduction of a new class of drugs, calcimimetics, allows improved control of abnormal calcium/phosphorus metabolism. The calcimimetics compliment, rather than replace, current treatment options for secondary hyperparathyroidism in the chronic disease patient.

引用

页码：S33 / S36

页数：4

共 21 条

[1] A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure -: Rapid communication [J].